Highly scalable reusable high-throughput ion exchange membrane chromatography
The "Mustang(R) Q XT Chromatography Capsule" is available in capacities of 5 mL, 50 mL, 140 mL, 450 mL, and 5 L, featuring a 16-layer pleated structure using a Mustang membrane at the tip, providing stable performance and scalability. It captures charged biomolecules in a single pass, demonstrating high binding capacity and flow rate with low pressure loss. The wide range of capsule sizes makes it suitable for various scales and binding capacities required in bioprocesses, from the development stage to full-scale production. 【Features】 - High binding capacity and flow rate with low pressure loss - High flow rate allows for large-scale processing within a day's working hours - Manufactured using a management system based on Six Sigma statistics - No need for cleaning or validation, eliminating the risk of cross-contamination *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Other Features】 ■ Elimination of filling and cleaning procedures that require validation, reducing operational costs and capital investment compared to conventional columns. ■ Compact design allows for efficient impurity removal with a very small amount of buffer. ■ Highly scalable design. ■ Robust and reusable capsule design with high scalability. ■ High-quality standards. *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Applications】 ■Removal of impurities such as DNA, viruses, host cell proteins, and endotoxins ■Capture of plasmids, viruses, proteins, and purification of oligonucleotides ■Column guard to enhance separation performance in chromatography processes *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.
